Quest Diagnostics delivered a solid Q2 with adjusted EPS of $3.12 and revenue of $3.043 billion, up 10.2% year over year and 10% organically. Broad demand across physician, hospital and consumer channels, plus partnerships with Corewell Health and Fresenius, buoyed volumes and lifted full-year guidance to 2026 targets. The results support a bullish near-term setup for DGX, assuming demand remains resilient and the volume mix stays favorable.
Quest Diagnostics reported a strong Q2 with revenues of about $3.04B and organic growth of 10%, prompting a lift in full-year 2026 guidance to $11.95–$12.05B and higher EPS ranges. Strategic collaborations (Corewell Health, Fresenius) and Haystack MRD NY approval underscore faster diagnostic adoption, while a continued buyback (~$100M) supports capital allocation. These drivers suggest accelerating earnings mix and potential multiple expansion for DGX stock over the medium term.
Quest Diagnostics has raised its profit and revenue forecasts for 2026, following first-quarter results that exceeded Wall Street estimates. The company cited resilient demand for routine diagnostic testing as a significant factor driving this optimistic outlook, suggesting continued growth potential in the diagnostics sector.
Quest Diagnostics projected its 2026 profit and revenue to exceed Wall Street expectations, driven by robust demand for diagnostic tests, following a strong performance in Q4. This optimistic outlook could positively influence investor sentiment towards similar companies in the diagnostics sector, including DGX.
Quest Diagnostics reported $2.76 billion revenue for Q2 2025. Earnings per share (EPS) stood at $2.62, exceeding expectations. Upward revision of full-year forecasts announced due to strong diagnostic demand.
